SCHEMBL16936604

SCHEMBL16936604

COc1ccc(Cn2nnnc2-c2c(-c3ccnc4ccccc34)ccc(Br)c2S(N)(=O)=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.46
BMP4 P12644 2/20 0.37
BMPR1B O00238 1/20 0.37
KDR P35968 1/20 0.37
BMPR1A P36894 1/20 0.37
ACVR1B P36896 1/20 0.37
TGFBR1 P36897 1/20 0.37
ACVRL1 P37023 1/20 0.37
TGFBR2 P37173 1/20 0.37
ACVR1 Q04771 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ERCC5 P28715 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16936800 0.89 P2RX7 (0.44) P2RX7BMP4CA12CA1CA2
SCHEMBL16936516 0.85 P2RX7 (0.50) P2RX7BMP4BMPR1BKDRBMPR1A
SCHEMBL18226931 0.79 PTGS2 (0.43) ALDH1A1ERCC5FEN1TOP2APTGS2
SCHEMBL16936754 0.79 PTGS2 (0.43) ALDH1A1LMNAERCC5FEN1TOP2A
SCHEMBL16936686 0.76 PTGS2 (0.42) P2RX7ALDH1A1LMNAERCC5FEN1
SCHEMBL16936523 0.76 RET (0.42)
SCHEMBL16936725 0.75 P2RX7 (0.48) P2RX7BMP4BMPR1BKDRBMPR1A
SCHEMBL16937050 0.75 P2RX7 (0.48) P2RX7BMP4BMPR1BKDRBMPR1A
SCHEMBL16937148 0.75 P2RX7 (0.49) P2RX7BMP4BMPR1BKDRBMPR1A
SCHEMBL16936349 0.74 PTGS2 (0.41) ALDH1A1LMNAERCC5FEN1TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3096754-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 EP disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA P2RX7 4162/4885BMP4 3237/4885BMPR1B 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.